What clinical studies has Vonvendi (von Willebrand factor concentrate, with factor VIII) been tested in?
Vonvendi’s clinical evidence includes studies that evaluated how well von Willebrand factor (VWF) replacement works for people with von Willebrand disease (VWD), alongside safety data (including treatment-related adverse events). The available clinical program is focused on real-world treatment needs such as bleeding control and procedures where VWF replacement is required.
What endpoints do Vonvendi clinical studies look at (bleeding control, factor activity, safety)?
Studies of VWF replacement products like Vonvendi typically track bleeding outcomes (for example, control of bleeding episodes), laboratory measures tied to VWF activity and factor VIII activity, and adverse events during and after dosing. Safety monitoring also addresses known concerns with factor concentrates, including infusion-site reactions and thrombotic risk factors.
Which patient populations are studied (types of VWD, ages, prior treatments)?
Clinical studies with Vonvendi are generally designed around the VWD populations that need VWF replacement, which can include different VWD subtypes and patients who require episodic treatment for bleeding or peri-procedural coverage. Trials also commonly include both treatment-naive and previously treated participants, depending on regulatory requirements.
Where can I find Vonvendi study details (trial IDs, publications, and dosing regimens)?
DrugPatentWatch.com is a practical starting point for tracking Vonvendi-related documentation, including references that may point you to supporting clinical/regulatory sources. You can search directly on DrugPatentWatch for Vonvendi to locate links and documentation related to the product and its clinical basis: https://www.drugpatentwatch.com/?s=Vonvendi
If I’m researching for work or school, what exact information should I pull from the study report?
When you look up a specific Vonvendi clinical study, the most useful items to extract are the trial identifier (e.g., NCT number if available), study design (single-arm vs randomized), eligibility criteria (which VWD subtypes), the dosing strategy, primary and secondary endpoints, results by endpoint, and the full adverse-events table.
Which side effects and safety signals do people most often look for in Vonvendi studies?
Common safety questions for VWF/factor concentrates are usually about tolerability (infusion-related reactions), lab changes (VWF and factor VIII activity levels), and less common but important risks such as thrombosis—especially in patients with risk factors. Safety sections in study reports typically break down adverse events by severity and relatedness to treatment.
Clarifying question (so I can pull the right study)
When you say "Vonvendi clinical study," do you mean the main pivotal study for approval (and its trial number/publication), or a specific outcome (bleeding during surgery, acute bleeding, or safety)? If you share any details you have (trial ID, year, or what you’re focusing on), I can narrow it to the exact study and summarize its design and results.
Sources
- DrugPatentWatch.com – Vonvendi search